Revised Risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States

Journal of Clinical Oncology

Volumn 33, Issue 2, 2015, Pages 195-201

  Frazier, A Lindsay ^a   Hale, Juliet P ^b   Rodriguez Galindo, Carlos ^a   Dang, Ha ^h   Olson, Thomas ^j   Murray, Matthew J ^c,d   Amatruda, James F ^k   Thornton, Claire ^e   Arul, G Suren ^f   Billmire, Deborah ^l   Shaikh, Furqan ^m   Pashankar, Farzana ⁿ   Stoneham, Sara ^g   Krailo, Mark ⁱ   Nicholson, James C ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^h Children's Oncology Group   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j EMORY UNIVERSITY   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l RILEY HOSPITAL FOR CHILDREN   (United States)

^m HOSPITAL FOR SICK CHILDREN   (Canada)

ⁿ YALE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AMIFOSTINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PLATINUM; TUMOR MARKER;

ADOLESCENT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BOOTSTRAPPING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CHILDHOOD CANCER; CHORIOCARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EMBRYONAL CARCINOMA; FEMALE; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; INFANT; LONG TERM DISEASE FREE SURVIVAL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY TUMOR; OVERALL SURVIVAL; PARAMETRIC TEST; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; TUMOR LOCALIZATION; UNITED KINGDOM; UNITED STATES; YOLK SAC TUMOR; AGE; CANCER STAGING; CLINICAL TRIAL (TOPIC); ENDODERMAL SINUS TUMOR; EVIDENCE BASED MEDICINE; GREAT BRITAIN; MORTALITY; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; VALIDATION STUDY;

ADOLESCENT; AGE FACTORS; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDODERMAL SINUS TUMOR; EVIDENCE-BASED MEDICINE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84920994767     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.3369     Document Type: Article

References (26)

1. Göbel U, Schneider DT, Calaminus G, et al: Multimodal treatment of malignant sacrococcygeal germ cell tumors: A prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol 19:1943-1950, 2001.
2. Mann JR, Raafat F, Robinson K, et al: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: Carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18:3809- 3818, 2000.
3. Cushing B, Giller R, Cullen JW, et al: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22:2691-2700, 2004.
4. Lopes LF, Macedo CR, Pontes EM, et al: Cisplatin and etoposide in childhood germ cell tumor: Brazilian pediatric oncology society protocol GCT-91. J Clin Oncol 27:1297-1303, 2009.
5. Poynter JN, Amatruda JF, Ross JA: Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer 116:4882-4891, 2010.
6. Travis LB, Ng AK, Allan JM, et al: Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 104:357- 370, 2012.
7. Travis LB, Fosså SD, Schonfeld SJ, et al: Second cancers among 40, 576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005.
8. Travis LB, Curtis RE, Hankey BF: Second malignancies after testicular cancer. J Clin Oncol 13:533-534, 1995.
9. Diller L, Chow EJ, Gurney JG, et al: Chronic disease in the Childhood Cancer Survivor Study cohort: A review of published findings. J Clin Oncol 27:2339-2355, 2009.
10. Rogers PC, Olson TA, Cullen JW, et al: Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A pediatric intergroup study-Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 22:3563-3569, 2004.
11. Baranzelli MC, Kramar A, Bouffet E, et al: Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 17:1212, 1999.
12. Marina N, London WB, Frazier AL, et al: Prognostic factors in children with extragonadal malignant germ cell tumors: A pediatric intergroup study. J Clin Oncol 24:2544-2548, 2006.
13. Frazier AL, Rumcheva P, Olson T, et al: Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer 50:746-751, 2008.
14. Sposto R: Cure model analysis in cancer: An application to data from the Children's Cancer Group. Stat Med 21:293-312, 2002.
15. Mann JR, Pearson D, Barrett A, et al: Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 63:1657-1667, 1989.
16. Malogolowkin MH, Krailo M, Marina N, et al: Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the Children's Oncology Group (COG). Pediatr Blood Cancer 60:1602-1605, 2013.
17. Billmire DF, Cullen JW, Rescorla FJ, et al: Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: Report from the Children's Oncology Group. J Clin Oncol 32:465-470, 2014.
18. Hollander N, Sauerbrei W, Schumacher M: Confidence intervals for the effect of a prognostic factor after selection of an "optimal" cutpoint. Stat Med 23:1701-1713, 2004.
19. Equivalence between international units and mass units of alpha-foetoprotein: Report of a collaborative study. Clin Chim Acta 96:59-65, 1979.
20. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data (ed 2). Hoboken, NJ, John Wiley & Sons, 2002.
21. Heagerty PJ, Lumley T, Pepe MS: Timedependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337-344, 2000.
22. Braga-Neto UM, Dougherty ER: Is crossvalidation valid for small-sample microarray classification? Bioinformatics 20:374-380, 2004.
23. Adra N, Oza A, Albany C, et al: A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 1990 to 2011. J Clin Oncol 32: 310s, 2014 (suppl; abstr 4557).
24. Cost NG, Lubahn JD, Adibi M, et al: A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. Pediatr Blood Cancer 61:446- 451, 2014.
25. Wu JT, Book L, Sudar K: Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 15:50-52, 1981.
26. Mazumdar M, Bajorin DF, Bacik J, et al: Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19: 2534-2541, 2001.